NL-OMON31740已完成2 期
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - AURA-6202-007
erviano Medical Sciences Srl, Italy0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Adult (age >= 18 years) male patients.
- •2. Histologically confirmed diagnosis of adenocarcinoma of the prostate.
- •3. Metastatic (stage D3 according to Jewett Staging System).
- •4. Hormone-refractory disease, progressing after 1st-line docetaxel-based chemotherapy. For patients with measurable disease, progression will be defined by RECIST criteria. For patients without any measurable disease, appearance of new bone lesions at bone scan and PSA progression, according to recommendations from the Prostate-Specific Antigen Working Group, will be required.
- •5. Patients receiving corticosteroids requested for concomitant disease other than HRPC should continue treatment at the same dose.
- •6. Patients receiving bisphosphonate therapy must have been on stable doses for at least 4 weeks prior to enrollment.
- •7. Patients who have not undergone surgical castration must continue on primary androgen deprivation with LHRH analogue, if any, and testosterone must be < 50 ng/dL.
- •8. Prior radiotherapy is allowed provided that no more than 25% of bone marrow reserve has been irradiated and a minimum of 4 weeks have elapsed between the end of prior radiotherapy and the entry into the trial.
- •9. ECOG performance status 0-2.
- •10. Life expectancy of at least 3 months.
- •11. Resolution of all acute toxic effects (excluding alopecia) of any prior surgery, radiotherapy, radio-surgery or chemotherapy to NCI CTC (Version 3.0) Grade >= 1.
- •12. Required baseline laboratory data include:
- •Absolute Neutrophils Count (ANC) >= 1.500/mm3 (>= 1,5 x 109/L)
- •Platelets >= 100.000/mm3 (>= 100 x 109/L)
- •Hemoglobin >= 10,0 g/dL
- •Serum Creatinine <=1,5 mg/dL ( <=133 *mol/L)
- •Serum Albumin >= 3,0 g/dL
- •Total Serum Bilirubin <= 1,5 x ULN
- •Liver Transaminases (AST/ALT) <= 2,5 x ULN; <= 5 x ULN if livermetastasis are present
- •Alkalische fosfatase (ALP) <= 2,5 x ULN; <= 5 x ULN if bonemetastasis are present
- •AST/ALT = aspartate aminotransferase/alanine aminotransferase, ULN = upper normal limit
- •13. Signed and dated informed consent indicating that the patient is aware of the neoplastic nature of his disease and has been informed of the procedures to be followed, the experimental nature of the therapy, potential benefits, side effects, discomforts, risks, and alternative treatments.
- •14. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.
排除标准
- •1. Current enrollment in another therapeutic clinical trial.
- •2. Use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to treatment.
- •3. More than one prior chemotherapy line.
- •4. Known brain or leptomeningeal disease (baseline computerized tomography [CT] or Magnetic Resonance Imaging [MRI] scan of the brain required only in case of clinical suspicion of central nervous system metastases.
- •5. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for 5 years or greater.
- •6. Prior treatment with radiopharmaceuticals (e.g. Strontium-89, Samarium-153) within 8 weeks prior to enrollment.
- •7. Major surgery, within 4 weeks or not fully recovered prior to Day 1.
- •8. Patients must agree to have no intention to father a child during the study and in the following 3 months after the end of the treatment.
- •9. Uncontrolled hypertension with blood pressure exceeding 160/100 mmHg (Stage 2 hypertension according to the JNC 7/ NIH USA 2003 guideline).
- •10. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis.
- •11. Cardiac dysrhythmias Grade >= 2 according to NCI CTCAE version 3.0.
- •12. Known active infections, including HIV positivity.
- •13. History of allergic reactions to a similar structural compound, biological agent, or formulation.
- •14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - NDTreatment of patients with metastatic hormone refractory prostate cancer.MedDRA version: 9.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-006136-21-ITERVIANO MEDICAL SCIENCES118
进行中（未招募）
1 期
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - not availableMetastatic hormone refractory prostate cancerMedDRA version: 9.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerEUCTR2006-006136-21-FRerviano Medical Sciences S.r.l.118
进行中（未招募）
不适用
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. - not availableEUCTR2006-006136-21-NLerviano Medical Sciences S.r.l.118
进行中（未招募）
不适用
A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy - NDTreatment of Chronic Myeloid LeukemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2006-006881-40-ITERVIANO MEDICAL SCIENCES16
进行中（未招募）
1 期
Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapyRecurrent or metastatic unresectable thymic carcinomaEUCTR2009-014338-79-FRerviano Medical Sciences S.r.l.60